RBC Capital Maintains Outperform on Kymera Therapeutics, Raises Price Target to $103

Benzinga · 1d ago
RBC Capital analyst Brian Abrahams maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target from $70 to $103.